Algernon Pharmaceuticals Invited to Present Phase 2 IPF and Chronic Cough Study Data at 9th American Cough Conference
Algernon Pharmaceuticals is pleased to announce its participation in the 9th American Cough Conference in June 2023, where it will present results from its Phase 2a Study of NP-120 (Ifenprodil) for idiopathic pulmonary fibrosis and chronic cough. Ifenprodil, an NMDA receptor antagonist, could pioneer new treatment avenues for these conditions. Dr. Peter Dicpinigaitis noted the drug's promising potential as a first-in-class therapy. The conference, which focuses on cough research and management, occurs biennially, highlighting the significance of this presentation.
- Invitation to present Phase 2a Study results at the 9th American Cough Conference, indicating recognition in the field.
- Ifenprodil could become a first-in-class treatment for idiopathic pulmonary fibrosis and chronic cough.
- None.
VANCOUVER, British Columbia, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage Canadian pharmaceutical development company, is pleased to announce it has been invited to present the results from its Phase 2a Study of NP-120 (“Ifenprodil”) for idiopathic pulmonary fibrosis (“IPF”) and Chronic Cough, at the 9th American Cough Conference in June, 2023.
The American Cough Conference is the world’s leading educational meeting for health care professionals involved in the research and management of patients with cough and is held every two years.
“I am pleased that Algernon has accepted our invitation to present at the American Cough Conference,” said Dr. Peter Dicpinigaitis, Professor of Medicine at Albert Einstein College of Medicine, Editor-in-Chief of LUNG, and conference chair. “The NMDA receptor is a fascinating target, and Ifenprodil, if successful, would be a first-in-class treatment. I am excited about the drug’s potential not only for cough in IPF, but also for the wider refractory chronic cough population.”
About Ifenprodil
Ifenprodil is an N-methyl-D-aspartate (NMDA) receptor antagonist specifically targeting the NMDA-type subunit 2B (GluN2B), which prevents glutamate signalling. Ifenprodil represents a novel first in class treatment for both IPF and chronic cough.
About Algernon Pharmaceuticals Inc.
Algernon is a drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.
CONTACT INFORMATION
Christopher J. Moreau
CEO
Algernon Pharmaceuticals Inc.
604.398.4175 ext 701
info@algernonpharmaceuticals.com
investors@algernonpharmaceuticals.com
www.algernonpharmaceuticals.com
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulators. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
FAQ
What is Algernon Pharmaceuticals presenting at the American Cough Conference 2023?
What is the significance of Ifenprodil in clinical studies?
When is the American Cough Conference taking place?
What are the implications of the Phase 2a Study results for AGNPF investors?
Who is involved in the American Cough Conference?
